START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC

Phase III study of stereotactic body radiation therapy (SBRT) plus standard of care in castration sensitive oligometastatic prostate cancer patients, defined as androgen deprivation therapy plus radiotherapy to the primary tumor in previously not treated patients and second generation hormonal treatments (Apalutamide/Abiraterone+Prednisone/Enzalutamide) vs androgen deprivation therapy plus radiotherapy to the primary tumor in previously not treated patients plus second generation hormonal treatments, for the treatment of oligometastatic prostate cancer.

Trial Details

NCT ID
NCT05209243
Phase
NA
Sponsor
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • SBRT
  • STANDARD OF CARE
Locations (sample)
  • Madrid, Spain|40.4165,-3.70256
  • Valencia, Spain|39.47391,-0.37966

Key Eligibility Criteria

  • Patients with a histological diagnosis of prostate cancer.
  • Castration sensitive prostate cancer patients.
  • Oligometastatic disease defined as less than or equal 3 lesions based on CT and Bone Scan and less than or equal 5 lesions based on Choline or PSMA…
  • Informed consent is obtained from the patient.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →